BIOCERES CROP SOLUTIONS CORP. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 11.26 USD | -1.92% |
|
-6.17% | -17.99% |
| May. 14 | Transcript : Bioceres Crop Solutions Corp., Q3 2024 Earnings Call, May 14, 2024 | |
| May. 14 | Bioceres Crop Solutions Fiscal Q3 Earnings, Revenue Fall | MT |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 67% by 2026.
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Analyst opinion has improved significantly over the past four months.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
- The company benefits from high valuations in earnings multiples.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Sector: Agricultural Chemicals
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -17.99% | 721M | - | ||
| +18.05% | 39.55B | C | ||
| -.--% | 11.33B | - | B+ | |
| +1.63% | 7.97B | A | ||
| +2.07% | 6.51B | B- | ||
| -4.35% | 6.06B | B+ | ||
| +0.72% | 5.92B | B | ||
| +37.82% | 5.57B | B- | ||
| -12.95% | 5.41B | - | C- | |
| -12.87% | 4.61B | C+ |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-
Valuation
P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- BIOX Stock
- Ratings Bioceres Crop Solutions Corp.